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AMP-activated protein kinase (AMPK) is an evolutionarily
conserved heterotrimer important for metabolic sensing in all
eukaryotes. The muscle-specific isoform of the regulatory -sub-
unit of the kinase, AMPK 3, has an important role in glucose
uptake, glycogen synthesis, and fat oxidation in white skeletal mus-
cle, as previously demonstrated by physiological characterization of
AMPK 3 mutant (R225Q) transgenic (TgPrkag3225Q) and 3
knock-out (Prkag3/) mice.We determinedAMPK3-dependent
regulation of gene expression by analyzing global transcription pro-
files in glycolytic skeletal muscle from 3 mutant transgenic and
knock-out mice using oligonucleotide microarray technology. Evi-
dence is provided for coordinated and reciprocal regulation ofmul-
tiple key components in glucose and fat metabolism, as well as skel-
etal muscle ergogenics in TgPrkag3225Q and Prkag3/ mice. The
differential gene expression profile was consistent with the physio-
logical differences between the models, providing a molecular
mechanism for the observed phenotype. The striking pattern of
opposing transcriptional changes between TgPrkag3225Q and
Prkag3/ mice identifies differentially expressed targets being
truly regulatedbyAMPKand is consistentwith the view thatR225Q
is an activating mutation, in terms of its downstream effects. Addi-
tionally, we identified a wide array of novel targets and regulatory
pathways for AMPK in skeletal muscle.
AMP-activated protein kinase (AMPK)2 is a critical regulator of car-
bohydrate and fat metabolism in eukaryotic cells (reviewed in Refs. 1
and 2). AMPK is a heterotrimer that consists of -, -, and -subunits,
all of which are required for its activity. The catalytic-subunit contains
a conventional serine/threonine protein kinase domain, and phospho-
rylation of Thr-172 residue within the activation loop of the -subunit
by upstream kinases is essential for the activity of the heterotrimer
(3–6). Once phosphorylated at Thr-172, AMPK can be further acti-
vated by allosteric binding of AMP to the evolutionary conserved cys-
tathionine -synthase domains in the regulatory -subunit (7). The
AMPK -subunit acts as a scaffold for binding of the - and -subunits
(8). The-subunit also contains a glycogen-binding domain, and recent
findings provide evidence that this motif is involved in targeting the
AMPK complex to cellular glycogen stores (9, 10). The mammalian
genome contains seven AMPK genes encoding for two -, two -, and
three -isoforms. Thus, there are 12 possible combinations of hetero-
trimeric AMPK, and the physiological function of the AMPK holoen-
zyme depends on the particular isoforms present in the complex.
We have provided evidence that AMPK 3 is the predominant -iso-
form expressed in glycolytic (white, fast-twitch type II) skeletal muscle
(11). In contrast, it is expressed at low levels in oxidative (red, slow-
twitch type I) skeletalmuscle and is undetectable in brain, liver, heart, or
white adipose tissue (11). Thus, the AMPK 3-subunit is the only iso-
form exhibiting tissue-specific expression. Furthermore, the AMPK
3-subunit primarily forms heterotrimerswith the2- and2-isoforms
in glycolytic skeletal muscle (11).
The functional significance of the AMPK 3-subunit has been dem-
onstrated by phenotypic analysis of animal models carrying a mutated
form of the gene. The dominant Rendement Napole (RN) phenotype
identified in Hampshire pigs is caused by a single missense mutation
(R225Q) in the AMPK 3-subunit (12). RN pigs have a 70% increase in
glycogen content in skeletal muscle, whereas liver and heart glycogen
content remains unchanged (13). Furthermore, RN carriers are also
characterized by a higher oxidative capacity in white skeletal muscle
fibers (14, 15). Conversely, a second mutation (V224I) identified in pigs
at the neighboring amino acid residue of the 3-protein is associated
with an opposite phenotype compared with the RN allele, resulting in
reduced skeletal muscle glycogen content (16). Characterization of
transgenic mice with skeletal muscle-specific expression of the mutant
(R225Q) form of the mouse AMPK 3-subunit, as well as AMPK
3-subunit knock-out mice, provided further evidence that the 3-sub-
unit plays a key role in skeletal muscle carbohydrate and lipid metabo-
lism. Glycogen resynthesis after exercise was impaired in AMPK 3
knock-outmice but wasmarkedly enhanced in transgenicmutantmice.
An AMPK-activator failed to increase skeletal muscle glucose uptake in
knock-out mice, whereas insulin-mediated glucose uptake was unal-
tered. When fed with a high fat diet, 3 R225Q transgenic mice were
protected against excessive triglyceride accumulation and insulin resist-
ance in skeletal muscle, presumably due to an increase in fat oxidation
(17). Additionally, skeletal muscle from 3 R225Qmutant mice is char-
acterized by enhanced work performance, whereas knock-out mice are
fatigue-prone (18).
To further characterize the role of AMPK 3 in skeletalmuscle and to
uncover molecular mechanisms explaining phenotypic consequences
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of the mutations in this isoform, we have studied AMPK 3-dependent
gene transcription by a systematic approach, using global analysis of the
mRNA expression pattern in the skeletal muscle of 3 R225Q mutant
and 3 knock-out mice. Here we describe distinct biomarker patterns,
comprising AMPK 3-dependent transcriptional changes of genes invo-
lved in glucose and lipid metabolism and skeletal muscle ergogenics.
EXPERIMENTAL PROCEDURES
AMPK Knock-out (Prkag3/) and R225Q Transgenic
(TgPrkag3225Q) Mice—The Prkag3/ and TgPrkag3225Q mice used in
this study have been previously described (17). Prkag3/ mice were
created by conventional gene targeting techniques. TgPrkag3225Q mice
express themutant 3 R225Q subunit under the control of mousemyo-
sin-light chain promoter and enhancer elements.Mice used in the study
were bred into the C57BL/6 genetic background.Mice weremaintained
in a 12-h light-dark cycle and were cared for in accordance with regu-
lations for the protection of laboratory animals. The study was per-
formed after prior approval from the local ethical committee. Gene
expression profiles were characterized in male mice fasted overnight
(food was removed 16 h prior to study). The white portion of the gas-
trocnemiusmuscle was dissected from anesthetizedmice, cleaned of fat
and blood, and quickly frozen in liquid nitrogen as described (17).
Preparation of Total RNA—Total RNA was isolated from the white
portion of the gastrocnemiusmuscle using the RNeasy FibrousMini Kit
(Qiagen) applying Mixer Mill MM 301 (Retsch) followed by a DNase
digestion step using RNase-Free DNase Set (Qiagen) according to the
manufacturer’s instructions. The RNA yield was quantified by spectro-
photometric analysis and the RNA purity was determined based on the
A260/A280 ratio. The quality of the RNA was confirmed by Agilent 2100
Bioanalyzer analysis (Agilent Technologies) using the RNA 6000 Nano
Assay Kit (Agilent Technologies).
Preparation of cRNA, Gene Chip Hybridization—10 g of total RNA
spiked with poly-A controls (pGIBS-TRP, -THR, and -LYS, American
Type Culture Collection) was converted to cDNA utilizing a T7 pro-
moter-polyT primer (Affymetrix) and the reverse transcriptase Super-
script II (Invitrogen), followed by a second strand cDNA synthesis
(Invitrogen). Double-stranded cDNA was in vitro transcribed to bioti-
nylated cRNA (Enzo) and then fragmented (Invitrogen). The frag-
mented cRNA was mixed with control oligonucleotide B2 (Affymetrix)
and a hybridization control cRNA mixture (BioB, BioC, BioD, and Cre,
Affymetrix). Aliquots of each sample were hybridized (16 h at 45 °C) to
GeneChip Mouse Expression Set 430A arrays (Affymetrix). The arrays
were subsequently washed, stained, and scanned according the manu-
facturer’s instructions (GeneChip Expression Analysis Technical Man-
ual, Affymetrix).
Data Analysis—Data were analyzed using GeneTraffic UNO 3.2–11
(Iobion Informatics) and Spotfire DecisionSite 8.1 (Spotfire Inc.). The
TgPrkag3225Q dataset was analyzed separately from the Prkag3/ data-
set. For further details see the supplemental information.
Quantitative Real-time PCR—Quantification of mRNA levels for
selected genes was performed by qRT-PCR as described (19) using
acidic ribosomal phosphoprotein P0 (Arbp) as endogenous control (see
supplemental Table SI for primer information). qRT-PCR was performed
on extended set of samples including 7 Prkag3/ mice with 8 wild-type
littermates and 13 TgPrkag3225Q mice with 10 wild-type littermates, while
RNA from 6 animals in each group was used in gene array analysis.
Histochemistry—Enzyme activity staining for succinate dehydrogen-
ase and cytochrome c oxidase was done on serial cross-sections (10-m
thickness) of frozen gastrocnemius muscle as described previously (20,
21). For succinate dehydrogenase activity staining, sections were incu-
bated for 4 min in a 0.1 M phosphate buffer (pH 7.6) containing 5 mM
EDTA, 45mM disodium succinate, 1.2mM nitro blue tetrazolium, 1mM
potassium cyanide, and 1 mM phenazine methosulfate. Cytochrome c
oxidase activity staining was performed by incubating sections for 1 h in
a 50 mM phosphate buffer (pH 7.6) containing 0.22 M sucrose, 2.3 mM
3,3-diaminobenzidine tetrahydrochloride, 1 mM cytochrome c, and
1300 units of catalase.
RESULTS
Microarray Analysis of the mRNA Expression in the Skeletal Mus-
cle of AMPK 3 Knock-out (Prkag3/) and R225Q Transgenic
(TgPrkag3225Q) Mice—To determine the role of 3-containing AMPK
complexes in regulation of gene expression in the skeletal muscle,
we utilized mouse models that either lack the AMPK 3-protein
(Prkag3/) or express a R225Qmutant form of this protein in skeletal
muscle (TgPrkag3225Q) (17). In Prkag3/mice, AMPK 3-protein
expression is completely ablated, and importantly, no compensatory
increase in 1- or 2-isoform is detected (17). Equally important,
AMPK expression in TgPrkag3225Q mice resembles the expression pat-
tern in wild-type mice, both with regard to tissue distribution and pro-
tein expression, with the mutant (R225Q) form replacing the endoge-
nous AMPK 3-protein (17). Global gene expression profiles in the
white portion of gastrocnemius muscle of Prkag3/ and TgPrkag3225Q
mice were compared with the corresponding wild-type littermates
using oligonucleotide microarrays. The expression of 167 genes was
significantly (p  0.05) changed by a factor of 20% or more, in
TgPrkag3225Q and/or Prkag3/ mice, relative to the wild-type controls
(Table 1). Applying the same filtering criteria on randomly created
groups within the Prkag3/ dataset and TgPrkag3225Q dataset resulted
in six genes determined as differentially expressed. This indicates
that the rate of false positives is low. Consequently, the vast majority
of the genes appearing differently expressed in Prkag3/ and/or
TgPrkag3225Q mice can be considered as truly regulated.
Of the 167 differentially expressed transcripts, the identity of 148
genes is known and represents proteins of different functional classes,
whereas 19 transcripts only show homology to sequences in the EST or
genomic databases. Interestingly, the expression level of 16 genes was
significantly changed in both AMPK 3 R225Q transgenic and AMPK
3 knock-out mice, compared with their respective wild-type litter-
mates (Table 1). For these 16 transcripts, the direction of the observed
change was the opposite in knock-out versus mutant transgenic mice.
Furthermore, most of the genes that were significantly changed exclu-
sively in Prkag3/ mice tended to be regulated in an opposite manner
in TgPrkag3225Q mice, even though this difference did not reach statis-
tical significance and/or meet the -fold change criteria. Correspond-
ingly, the vast majority of transcripts, which were differentially regu-
lated exclusively in R225Q transgenic mice, exhibited an opposite trend
in knock-out mice. The striking pattern of opposing transcriptional
changes in the AMPK 3 R225Q transgenic versus knock-out mice, as
compared with their wild-type littermates, is illustrated (Fig. 1).
Many of the genes, which were found to be differentially expressed in
Prkag3/ and/or TgPrkag3225Q mice, are previously undescribed as
being regulated by AMPK. Full functional significance of these changes
in global transcriptional profile remains to be addressed in further
experiments. To determine the possible mechanistic explanations for
previously described physiological differences between Prkag3/ and
TgPrkag3225Q mice (17, 18), we performed a more detailed analysis of
gene expression changes for targets that are known to be involved in
lipid and carbohydrate metabolism andmuscle ergogenics. The expres-
sion of several genes involved in these functions depends on the skeletal
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TABLE 1
Differentially expressed genes in TgPrkag3225Q and/or Prkag3/ mice compared with wild-type littermates
Global mRNA expression pattern was characterized in the white portion of the gastrocnemius skeletal muscle in male mice of C57BL/6 genetic background. The filtering
criteria were set to a mean absolute -fold change 1.2 and a p value 0.05. In addition the mean intensity in the group showing highest expression should be 75.





-Fold change p value -Fold change p value
Genes differentially expressed in both TgPrkag3225Q and Prkag3/ compared with wild-type littermates
AU017649 Gdap1a Ganglioside-induced differentiation-associated-
protein 1
1.82 0.0004 1.27 0.003
BB336256 Mafa v-maf musculoaponeurotic fibrosarcoma oncogene
family, protein A
1.58 0.000008 1.29 0.002
BC026377 Rasd2a RASD family, member 2 1.53 0.00005 1.21 0.048
NM_010016 Daf1a Decay accelerating factor 1 1.50 0.002 1.20 0.018
M62838 Slc7a2a Solute carrier family 7, member 2 1.46 0.006 1.35 0.023
BB414515 Slc2a3a Solute carrier family 2, member 3 1.42 0.002 1.22 0.035
BB326929 Sh3kbp1 SH3-domain kinase binding protein 1 1.41 0.010 1.23 0.011
NM_028803 Gbe1 Glucan branching enzyme 1 1.40 0.012 1.28 0.011
AI788759 Ugp2a UDP-glucose pyrophosphorylase 2 1.39 0.0001 1.21 0.008
AF226613 Slc40a1 Solute carrier family 40, member 1 1.38 0.006 1.26 0.019
NM_009876 Cdkn1c Cyclin-dependent kinase inhibitor 1C 1.32 0.0005 1.20 0.022
AV337591 Xpr1 Xenotropic and polytropic retrovirus receptor 1 1.26 0.009 1.21 0.005
BM114165 Rpl5 Ribosomal protein L5 1.24 0.015 1.21 0.024
NM_009079 Rpl22 Ribosomal protein L22 1.24 0.007 1.20 0.00004
AV030603 2010109N14Rik RIKEN clone 2010109N14 1.22 0.010 1.21 0.037
BC011152 Golph2 Golgi phosphoprotein 2 1.22 0.003 1.25 0.002
Genes differentially expressed in TgPrkag3225Q compared with wild-type littermates
NM_007913 Egr1 Mus musculus early growth response 1 2.36 0.021 1.05 0.887
BC024613 Tmem37 M. musculus transmembrane protein 37 2.03 0.000007 1.16 0.375
NM_008161 Gpx3 Glutathione peroxidase 3 1.90 0.000004 1.14 0.030
NM_007570 Btg2a B-cell translocation gene 2, anti-proliferative 1.76 0.023 1.11 0.535
NM_026433 1810057C19Rik Integral membrane protein 1.64 0.0004 1.09 0.607
NM_008357 Il15 Interleukin 15 1.57 0.00007 1.06 0.059
AI315015 Ces3a Carboxylesterase 3 1.57 0.018 1.10 0.513
NM_008416 Junb Jun-B oncogene 1.56 0.043 1.03 0.864
AK011596 Tfrc Transferrin receptor 1.54 0.040 1.09 0.315
X14678 Zfp36a Zinc finger protein 36 1.49 0.041 1.03 0.824
BG065702 D230025D16Rika RIKEN cDNA D230025D16 gene 1.47 0.023 1.01 0.823
NM_025427 RGC-32a Response gene to complement 32 (Homo sapiens) 1.47 0.009 1.05 0.686
NM_023065 Ifi30 Interferon -inducible protein 30 1.46 0.00007 1.10 0.094
C81193 Odc1a Ornithine decarboxylase, structural 1 1.46 0.002 1.17 0.052
BC010758 Cbr2 Carbonyl reductase 2 1.45 0.003 1.10 0.179
AK012825 2810026P18Rik RIKEN cDNA 2810026P18 gene 1.45 0.016 1.18 0.066
BC024118 9430059P22Rika Transmembrane protein 46 1.44 0.006 1.16 0.178
U18812 Lep Leptin 1.43 0.019 1.11 0.158
NM_010858 Myl4 Myosin, light polypeptide 4 1.43 0.0002 1.18 0.039
BB221402 Cidec Cell death-inducing DFFA-like effector c 1.43 0.040 1.20 0.058
BB794641 Nos1 Nitric-oxide synthase 1, neuronal 1.39 0.00007 1.17 0.009
NM_008452 Klf2 Kruppel-like factor 2 1.38 0.027 1.00 0.968
AF378088 Rhoua Ras homolog gene family, member U 1.37 0.004 1.00 0.945
BM200248 Peg3 Paternally expressed 3 1.37 0.015 1.02 0.790
NM_013525 Gas5a Growth arrest-specific 5 1.36 0.004 1.17 0.043
NM_026524 Mid1ip1 Mid1 interacting protein 1 1.34 0.004 1.20 0.197
AJ132394 Rorc RAR-related orphan receptor gamma 1.34 0.003 1.11 0.041
BC026450 Cova1 Cytosolic ovarian carcinoma antigen 1 1.34 0.006 1.15 0.148
BB039269 Gja1 Gap junction membrane channel protein alpha 1 1.34 0.030 1.01 0.873
BG069413 Klf4 Kruppel-like factor 4 1.33 0.023 1.03 0.739
BB644164 Cugbp2a CUG triplet repeat, RNA binding protein 2 1.32 0.011 1.08 0.437
BC012405 2310001H12Rik Gonadotropin-regulated transcription factor 1.32 0.022 1.04 0.436
BB144704 Abca1 ATP-binding cassette, sub-family A, member 1 1.32 0.006 1.16 0.023
BM120823 Eif4el3 Eukaryotic translation initiation factor 4E-like 3 1.32 0.004 1.06 0.485
AF176524 Fbxl10 F-box and leucine-rich repeat protein 10 1.32 0.002 1.13 0.094
BC011116 M6prbp1 Mannose-6-phosphate receptor binding protein 1 1.30 0.013 1.05 0.327
NM_010866 Myod1 Myogenic differentiation 1 1.30 0.0009 1.00 0.978
AI326423 Srebf1 Sterol regulatory element binding factor 1 1.29 0.0009 1.17 0.014
BB475271 Luc7l2 LUC7-like 2 (S. cerevisiae) 1.29 0.038 1.02 0.783
NM_022019 Dusp10 Dual specificity phosphatase 10 1.29 0.034 1.18 0.193
BC010564 Hist2h2aa1 Histone 2, H2aa1 1.29 0.0007 1.14 0.010
NM_007394 Acvr1 Activin A receptor, type 1 1.28 0.009 1.11 0.122
BC025461 Tm4sf3 Transmembrane 4 superfamily member 3 1.28 0.019 1.15 0.100
NM_010761 Ccndbp1 Cyclin D-type binding protein 1 1.28 0.007 1.09 0.232
BC022110 Alas1 Aminolevulinic acid synthase 1 1.28 0.00005 1.09 0.154
BF467211 Cdc42 Cell division cycle 42 homolog (S. cerevisiae) 1.28 0.001 1.13 0.036
AJ306425 Hfe Hemochromatosis 1.27 0.021 1.17 0.004
NM_009665 Amd1 S-Adenosylmethionine decarboxylase 1 1.27 0.021 1.08 0.363
NM_008735 Nrip1 Nuclear receptor interacting protein 1 1.27 0.024 1.00 0.990
NM_015753 Zfhx1b Zinc finger homeobox 1b 1.27 0.012 1.06 0.545
NM_026481 2700055K07Rik CGI-38 1.27 0.00002 1.16 0.108
BC015254 Cmkor1 Chemokine orphan receptor 1 1.27 0.022 1.06 0.567
NM_020604 Jph1 Junctophilin 1 1.26 0.019 1.05 0.663
BF577544 Pole4 Polymerase epsilon 4 1.26 0.021 1.04 0.375
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-Fold change p value -Fold change p value
NM_009523 Wnt4 Wingless-related MMTV integration site 4 1.26 0.0001 1.13 0.018
BB114336 Bace1 -Site APP cleaving enzyme 1 1.26 0.036 1.04 0.550
AK004781 Sox17 SRY-box containing gene 17 1.26 0.003 1.01 0.950
BC014718 Dnase1 Deoxyribonuclease I 1.25 0.001 1.16 0.115
AW988981 1110008H02Rik RIKEN cDNA 1110008H02 gene 1.25 0.006 1.19 0.166
NM_011430 Sncg Synuclein, gamma 1.25 0.021 1.03 0.638
NM_010240 Ftl1 Ferritin light chain 1 1.25 0.015 1.00 0.959
BC009165 Thrsp Thyroid hormone-responsive SPOT14 homolog
(Rattus)
1.25 0.027 1.01 0.931
NM_008393 Irx3 Iroquois-related homeobox 3 (Drosophila) 1.25 0.012 1.00 0.953
NM_009379 Thpo Thrombopoietin 1.25 0.004 1.11 0.024
NM_008258 Hn1 Hematological and neurological expressed
sequence 1
1.25 0.009 1.02 0.782
BG070255 Pde7aa Phosphodiesterase 7A 1.25 0.028 1.10 0.141
NM_015797 Fbxo6b F-box only protein 6b 1.24 0.010 1.07 0.080
BC010712 Cri1 CREBBP/EP300 inhibitory protein 1 1.24 0.026 1.02 0.763
BB261602 Map2k6 Mitogen-activated protein kinase kinase 6 1.24 0.030 1.07 0.107
U43884 Idb1 Inhibitor of DNA binding 1 1.24 0.033 1.05 0.473
BB278286 1810073P09Rik mKIAA1760 1.24 0.013 1.02 0.659
AK004847 Rnf128a Ring finger protein 128 1.24 0.015 1.07 0.176
AK018605 4631408O11Rik RIKEN cDNA 4631408O11 gene 1.24 0.039 1.01 0.883
BB039247 C1qr1 Complement component 1, q subcomponent,
receptor 1
1.24 0.007 1.00 0.991
AV276428 BC043118 cDNA sequence BC043118 1.24 0.002 1.10 0.036
AK018482 Fbxo9 F-box only protein 9 1.24 0.031 1.01 0.866
BB066232 Catna1 Catenin  1 1.24 0.047 1.01 0.913
BI143942 Sdh1a Sorbitol dehydrogenase 1 1.24 0.0007 1.01 0.903
BB359043 1700007D05Rik Transcription termination factor-like protein 1.23 0.016 1.09 0.060
BC021914 Mmd Monocyte to macrophage differentiation-
associated
1.23 0.042 1.00 0.983
AK020120 Hrmt1l2 Heterogeneous nuclear ribonucleoproteins
methyltransferase-like 2 (S. cerevisiae)
1.23 0.043 1.10 0.652
AK010029 Oxct1a 3-Oxoacid-CoA transferase 1 1.23 0.001 1.10 0.024
BM935811 Itga6 Integrin  6 1.23 0.016 1.02 0.786
BB818702 4933439F18Rik RIKEN cDNA 4933439F18 gene 1.23 0.015 1.07 0.069
BE986849 Ppp1r14b Protein phosphatase 1, regulatory subunit 14B 1.23 0.00002 1.11 0.005
BB145101 1110028E10Rik Choline transporter-like properties 1.23 0.003 1.09 0.221
BC019757 Hist1h4i Histone 1, H4i 1.22 0.016 1.12 0.231
AV336908 Dlat Dihydrolipoamide S-acetyltransferase 1.22 0.019 1.12 0.080
AB031049 Rev3l REV3-like 1.22 0.002 1.05 0.569
BB033733 Trim16 Tripartite motif protein 16 1.22 0.021 1.02 0.565
AB032010 Fxyd6 FXYD domain-containing ion transport regulator 6 1.22 0.020 1.04 0.362
NM_009214 Sms Spermine synthase 1.22 0.026 1.10 0.199
AW543698 Cdh5 Cadherin 5 1.22 0.009 1.04 0.299
BC023112 Galnact2 Chondroitin sulfate GalNAcT-2 1.21 0.041 1.13 0.058
NM_024439 H47 Histocompatibility 47 1.21 0.026 1.14 0.022
NM_020581 Angptl4 Angiopoietin-like 4 1.21 0.011 1.05 0.287
AF289490 Aspha Aspartate--hydroxylase 1.21 0.023 1.18 0.001
BC008105 Polk Polymerase, kappa 1.21 0.0005 1.08 0.166
NM_018832 Pdzx PDZ domain containing, X chromosome 1.21 0.016 1.05 0.328
AF276917 Glrx1 Glutaredoxin 1 (thioltransferase) 1.21 0.018 1.17 0.016
NM_007472 Aqp1 Aquaporin 1 1.21 0.010 1.04 0.294
AW741459 Eif4b Eukaryotic translation initiation factor 4B 1.21 0.005 1.07 0.130
NM_009076 Rpl12 Ribosomal protein L12 1.21 0.015 1.10 0.224
C78422 Coq3 Coenzyme Q3 homolog, methyltransferase (yeast) 1.21 0.013 1.08 0.036
BI739053 Clcn3 Chloride channel 3 1.21 0.039 1.02 0.866
NM_008173 Nr3c1 Nuclear receptor subfamily 3, group C, member 1 1.21 0.009 1.14 0.191
NM_022310 Hspa5 Heat shock 70-kDa protein 5 (glucose-regulated
protein)
1.21 0.007 1.14 0.024
BG801851 Actr1b ARP1 actin-related protein 1 homolog B (yeast) 1.20 0.040 1.01 0.946
AW989410 Pbef1 Pre-B-cell colony-enhancing factor 1 1.20 0.005 1.13 0.016
NM_138953 Ell2 Elongation factor RNA polymerase II 2 1.20 0.023 1.15 0.297
BB667778 Neo1 Neogenin 1.20 0.00003 1.08 0.043
NM_010437 Hivep2 Human immunodeficiency virus type I enhancer
binding protein 2
1.20 0.027 1.01 0.877
NM_016959 Rps3a Ribosomal protein S3a 1.20 0.00009 1.06 0.067
NM_007508 Atp6v1a1 ATPase, H transporting, V1 subunit A, isoform 1 1.20 0.002 1.01 0.894
BC022959 Acsl6 Acyl-CoA synthetase long-chain family member 6 1.20 0.025 1.01 0.735
AK003350 5730454B08Rik Zinc finger CCCH-type domain containing 11A 1.20 0.007 1.06 0.067
BC003451 Mat2a Methionine adenosyltransferase II,  1.20 0.037 1.15 0.225
Genes differentially expressed in Prkag3/ compared with wild-type littermates
NM_021537 Stk25 Serine/threonine kinase 25 (yeast) 1.00 0.913 1.88 0.00003
AK009959 Ankrd1a Ankyrin repeat domain 1 1.23 0.141 1.48 0.030
D87867 Ugt1a12a UDP-glycosyltransferase 1 family polypeptide
members A12, A10, A5, A6, A1, and A2
1.10 0.328 1.42 0.009
AK009828 Neu2 Neuraminidase 2 1.17 0.002 1.42 0.000004
BC019124 Lmcd1 LIM and cysteine-rich domains 1 1.09 0.356 1.40 0.010
AMPK 3-dependent Transcriptional Responses
MARCH 17, 2006 • VOLUME 281 • NUMBER 11 JOURNAL OF BIOLOGICAL CHEMISTRY 7247
muscle fiber type, and, correspondingly, any alterations in skeletal mus-
cle fiber type composition might contribute to expression differences.
However, relative expression of slow and fast myosin and troponin iso-
forms remained unchanged in TgPrkag3225Q or Prkag3/ mice versus
their respective wild-type littermates (data not shown).Moreover, enzyme
activity staining for succinate dehydrogenase and cytochrome c oxidase
(markers for oxidative energymetabolism that stain redmuscle fibers con-
taining high levels ofmitochondriamore intensively thanwhite fibers with
fewermitochondria) did not show any clear alteration in fiber type compo-
sition between the different genotypes (supplementary Fig. S1). Taken
together, these data indicate that differences in the transcriptional profile
we describe are independent of skeletal muscle fiber type changes.
qRT-PCRValidation of Differentially ExpressedGenes—Tominimize
erroneous conclusions due to technical variability of the microarray
technology, qRT-PCR analysis was applied to validate expression pro-
files of 13 genes selected on the basis of biological relevance (Fig. 2). For
all the transcripts examined, qRT-PCR data verified the significant dif-
ferences in gene expression (-fold change 1.2; p  0.05) detected by
gene array analysis. Furthermore, individual animal-to-animal compar-
ison of the expression profiles for these genes showed close to perfect
correlation comparing the two techniques (data not shown). The high
level of correlation between the expression profiles generated by
microarray versus qRT-PCR approach illustrates the reliability of the
gene array results. However, for 11 of 13 transcripts examined the
microarray data tended to underestimate the expression change com-
pared with qRT-PCR results.
Altered Expression of Components of the Glycogen Synthesis Pathway
in AMPK 3 Knock-out and R225Q Transgenic Mice—AMPK function
is closely connected to glycogen storage. In human and rat skeletal mus-
cle, high glycogen content represses AMPK activity (22, 23). Concomi-
tantly, there is also genetic evidence that AMPK regulates glycogen
levels, because mutations of the 3- or 2-subunit affect glycogen stor-
age in skeletal muscle of RN pigs or in human cardiac muscle, respec-
tively (12, 16, 24). Furthermore, AMPK 3 R225Q transgenic and 3
knock-out mice have a respective increase or decrease in the rate of
glycogenesis in the recovery phase following exercise (17). Notably,
the expression of two transcripts encoding proteins involved in gly-
cogen synthesis, Ugp2 and Gbe1, was significantly up-regulated in
TgPrkag3225Q mice, while being significantly down-regulated in
Prkag3/ mice, as determined by the microarray analysis (Table 1).
The observed change in the expression pattern was further confirmed
by a qRT-PCR approach (Fig. 2). Ugp2 codes for UDP-glucose pyro-
phosphorylase 2 (EC 2.7.7.9), an enzyme catalyzing the synthesis of
UDP-glucose, a common substrate for glycogenin and glycogen syn-
thase. Glycogenin catalyzes the first step in glycogen synthesis: a self-
glycosylation reaction to form an oligosaccharide chain of around eight
residues in length (25). Secondly, glycogen synthase (EC 2.4.1.11), with
the participation of the glycogen branching enzyme, Gbe1 (EC 2.4.1.18),
elongates the oligosaccharide chain to form a mature glycogen mole-
cule. Thus, coordinated changes inUgp2 andGbe1 expression are likely
to contribute to the differences in the glycogen synthesis rate observed
comparing Prkag3/ and TgPrkag3225Q muscle.
Coordinated and Reciprocal Changes in the Expression of Map2k6
and Dusp10 Genes in Prkag3/ and TgPrkag3225Q Muscle—Based
on correlative evidence, stimulation of glucose uptake has been
reported to be partly regulated by Mapk14 (also known as p38
MAPK), a downstream target of AMPK (26–30). However, the exact
mechanism of how the activation of AMPK would lead to an increase
TABLE 1—CONTINUED





-Fold change p value -Fold change p value
AV152334 Atp1b1a ATPase, Na/K transporting, 1 polypeptide 1.14 0.395 1.37 0.004
NM_009208 Slc4a3 Solute carrier family 4, member 3 1.04 0.653 1.34 0.010
BB534670 Cd36 CD36 antigen 1.08 0.658 1.33 0.008
AJ288061 Clasp1 CLIP associating protein 1 1.00 0.935 1.32 0.006
NM_024264 Cyp27a1 Cytochrome P450, family 27, subfamily a,
polypeptide 1
1.17 0.102 1.30 0.001
AK004757 Stk11ip Serine/threonine kinase 11 interacting protein 1.02 0.815 1.29 0.00003
AK007410 Gadd45g Growth arrest and DNA-damage-inducible 45 1.13 0.617 1.27 0.010
NM_016894 Ramp1 Receptor activity modifying protein 1 1.02 0.780 1.26 0.005
NM_013626 Pam Peptidylglycine -amidating monooxygenase 1.04 0.272 1.26 0.001
NM_013750 Phlda3 Pleckstrin homology-like domain, family A,
member 3
1.16 0.003 1.25 0.026
BM207588 Slc2a1 Solute carrier family 2 (facilitated glucose
transporter), member 1
1.13 0.203 1.25 0.022
BB085604 2610031L17Rik putative mitochondrial outer membrane protein
import receptor
1.01 0.965 1.25 0.008
AA792094 Got1 Glutamate oxaloacetate transaminase 1, soluble 1.17 0.016 1.24 0.011
BC013271 Anxa8 Annexin A8 1.07 0.211 1.24 0.009
AF335325 Ddit4l DNA-damage-inducible transcript 4-like 1.21 0.087 1.23 0.013
BF225802 Igfbp5 Insulin-like growth factor-binding protein 5 1.17 0.211 1.22 0.045
AV337619 Ppargc1a PPAR, coactivator 1 1.06 0.531 1.22 0.007
M64279 Bmi1 B lymphoma Mo-MLV insertion region 1 1.27 0.072 1.22 0.043
BG060909 Scd2 Stearoyl-Coenzyme A desaturase 2 1.00 0.964 1.22 0.003
M65053 Fgfr1 Fibroblast growth factor receptor 1 1.20 0.096 1.22 0.008
BB503267 C330005L02Rik Hypothetical mitochondrial energy transfer
proteins
1.10 0.210 1.21 0.015
BB044517 5730551F12Rik RIKEN cDNA 5730551F12 gene 1.02 0.830 1.21 0.024
AK004359 Tmcc2 Transmembrane and coiled-coil domains 2 1.19 0.003 1.21 0.00002
AV171622 3300001H21Rik RIKEN cDNA 3300001H21 gene 1.14 0.281 1.20 0.033
BC024809 Apbb3 Amyloid  precursor protein-binding, family B,
member 3
1.08 0.072 1.20 0.026
AV023018 Rpea Ribulose-5-phosphate-3-epimerase 1.23 0.058 1.20 0.049
AI324936 Rpl13a Ribosomal protein L13a 1.13 0.002 1.20 0.005
BB000894 Mtap4 Microtubule-associated protein 4 1.19 0.006 1.20 0.003
BG064031 Nap1l1a Nucleosome assembly protein 1-like 1 1.17 0.041 1.20 0.014
a Genes having several probe sets supporting the regulation.
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in Mapk14 phosphorylation remains obscure. Interestingly, two
transcripts encoding proteins involved in regulation of Mapk14
activity, Map2k6 and Dusp10, were coordinately regulated in 3
R225Q transgenic and knock-out mice, as shown bymicroarray anal-
ysis as well as qRT-PCR (Fig. 2). A protein encoded by Map2k6
(mitogen-activated protein kinase kinase 6) is known to activate
Mapk14 by dual phosphorylation of specific threonine and tyrosine
residues (31). Dusp10 (dual specificity phosphatase 10), on the other
hand, down-regulates the enzymatic activity of MAPKs by dephos-
phorylating the threonine and tyrosine residues, with selectivity
toward Mapk14 (32). Thus, the finding of an up-regulation of
Map2k6 in combination with a suppression of the Dusp10 transcript
in TgPrkag3225Q mice, and the reversed pattern of changes seen in
Prkag3/ mice, suggests that Mapk14 is a target of AMPK 3-con-
taining trimers in the skeletal muscle. An up-regulation of Map2k6
mRNA in TgPrkag3225Q muscle was accompanied by an increase in
the protein level, as seen by Western blot analysis (data not shown).
3-Containing AMPK Heterotrimers Regulate Lipid Metabolism
Gene Expression in Skeletal Muscle—The AMPK 3-subunit has previ-
ously been shown to be involved in regulation of fat oxidation. Pigs and
mice carrying the R225Qmutation in AMPK 3-gene are characterized
by increased lipid oxidation in skeletal muscle (14, 15, 17). In the
microarray and qRT-PCR analysis, several genes involved in fat metab-
olism were differentially expressed in TgPrkag3225Q and Prkag3/
mice, suggesting that 3-containing AMPK complexes are involved in
the regulation of lipid oxidation in skeletal muscle at the transcriptional
level. mRNA for Srebf1 (sterol regulatory element binding factor 1),
implicated in lipogenic gene expression (33), was down-regulated in 3
R225Q mutant mice, whereas mRNA encoding for Ppargc1a (peroxi-
some proliferative-activated receptor,  coactivator 1 ), known to
increase the expression of both nuclear and mitochondrial-encoded
genes of oxidative metabolism (34), was up-regulated. Additionally, a
key gene integral to free fatty acid uptake (Cd36 (35)), as well as genes
involved in use of fat-derived energy (3-oxoacid-CoA transferase 1,
Oxct1, EC 2.8.3.5 and carboxylesterase 3,Ces3, EC 3.1.1.1) were up-reg-
ulated in TgPrkag3225Q mice. The opposite pattern of changes was
observed in 3 knock-out mice, with differential expression of mRNA
for Cd36, Oxct1, and Ppargc1a reaching statistical significance (Fig. 2).
FIGURE 1. Hierarchical clustering of 167 genes differentially expressed in AMPK 3
R225Q transgenic and/or knock-out mice, compared with the corresponding wild-
type littermates. Euclidean distance is used as similarity measure. Each lane represents
one individual mouse, and each horizontal stripe represents a single gene transcript. The
colors represent the gene expression level in each individual mouse relative the average
expression of their corresponding wild-type group, with green indicating down-regula-
tion and red indicating up-regulation.
FIGURE 2. Expression analysis by qRT-PCR. The
number associated with each bar indicates the
-fold change in the AMPK 3 R225Q transgenic or
knock-out mice relative their wild-type litter-
mates. NC indicates no change and corresponds to
a -fold change of 1 or 1. Statistical differences
among genotypes were determined by two-sided
Student’s t test (*, p  0.05; **, p  0.01; and ***,
p  0.001).
AMPK 3-dependent Transcriptional Responses
MARCH 17, 2006 • VOLUME 281 • NUMBER 11 JOURNAL OF BIOLOGICAL CHEMISTRY 7249
Possible Role for the AMPK 3-Subunit in the Regulation of Cellular
Iron Homeostasis—Expression of several genes involved in iron metab-
olism was coordinately changed in AMPK 3 R225Q transgenic mice,
compared with the wild-type littermates. The transferrin receptor, fer-
ritin, and aminolevulinic acid synthase (a key enzyme for heme synthe-
sis) regulate the uptake, storage, and use of iron in cells, respectively.
Expression of these markers is known to be coordinately controlled by
cellular iron supply such that, under conditions of iron starvation, the
transferrin receptor is up-regulated, whereas ferritin and aminolevu-
linic acid synthase are down-regulated (36). In TgPrkag3225Q mice, the
transcription of the transferrin receptor, Tfrc was decreased, while
mRNAs for ferritin light chain 1 and aminolevulinic acid synthase 1
were increased, suggesting the possibility of improved iron status com-
pared with the wild-type mice (Fig. 2). Improved iron status may
increase skeletal muscle capacity for aerobicmetabolism (37, 38). In line
with this, the level of skeletal muscle myoglobin, a heme-carrying pro-
tein, transporting oxygen to the mitochondria, was non-significantly
increased inTgPrkag3225Qmice, as determined byWestern blot analysis
(data not shown).
AMPK 3-Containing Complexes Regulate Transcription of the Nos1
Gene—Nitric oxide synthase 1 (Nos1 also known as nNos) was signifi-
cantly up- and down-regulated by 2-fold in 3 R225Q transgenic and
knock-out mice, respectively (Fig. 2). The family of Nos enzymes cata-
lyzes formation of endogenous nitric oxide, a mediator implicated in
regulation of skeletal muscle contractility, mitochondrial function, as
well as glucose uptake (39, 40). Thus, the direction of differential expres-
sion of this gene was in complete agreement with the observed pheno-
type in the mouse models. Although Nos1 is considered a predominant
isoform expressed in skeletal muscle fibers, endothelial Nos3 (Nos3 or
eNos) and inducible Nos2 (Nos2 or iNos) are also expressed in this
tissue (41–43). Interestingly,Nos2 andNos3were represented on oligo-
nucleotidemicroarray andwere detected in the skeletalmuscle samples.
However, mRNA levels for these two genes were unaltered.
DISCUSSION
The present study provides the first systematic characterization of
the role of the 3-containing AMPK heterotrimers in transcriptional
regulation in skeletal muscle. An oligonucleotide microarray technol-
ogy was used to compare global transcriptional profiles in white skeletal
muscle from AMPK 3 R225Q transgenic (TgPrkag3225Q) and knock-
out (Prkag3/) mice and their respective wild-type littermates. Collec-
tively, evidence is provided for an important role of the AMPK 3-sub-
unit in the transcriptional regulation of divergent groups of genes in
glycolytic skeletal muscle. The expression of 167 genes was significantly
changed (-fold change  1.2 and p  0.05) in skeletal muscle from 3
R225Q transgenic and/or knock-out mice. A number of genes from the
same biological pathways was coordinately regulated. Changes in levels
of mRNA of particular interest, including genes involved in glycogen
and lipidmetabolism, aswell as iron homeostasis andMapk14 signaling,
were selected to be further verified by qRT-PCR (Fig. 2). For all of 13
selected genes, the qRT-PCR results were consistent with the gene array
data, which emphasizes the quality of the microarray results. Of note is
that most of the genes differentially regulated in TgPrkag3225Q mice
were changed in an opposing manner in AMPK 3 knock-out mice
(Fig. 1). The reciprocal and coordinated expression pattern observed
increases the confidence in the gene-array data and demonstrates that
the majority of differentially expressed genes are true positives.
This reverse transcription pattern seen in TgPrkag3225Q versus
Prkag3/ mice is intriguing, considering that the mechanism of action
of R225Q substitution in AMPK 3-subunit is still unresolved. A previ-
ous report provided evidence that the kinase activity of AMPK was
reduced by 3-fold in skeletal muscle of 3 R225Q mutant pigs when
measured in the presence and absence of the allosteric activator, AMP
(12). Nevertheless, in resting muscle from TgPrkag3225Q mice, AMPK
activity was unaltered (18). Excessive glycogen content characterizing
skeletal muscle of mice and pigs carrying the 3 R225Q mutation may
inhibit AMPKactivation by a feedbackmechanism.Consistentwith this
hypothesis, AMPK activity and phosphorylation of the Thr172 residue in
the -subunit was elevated in Cos cells transiently transfected with
plasmids encoding 223 R225Q, compared with the cells transfected
with plasmids encoding wild-type trimers (17). Interestingly, the intro-
duction of the R225Q mutation at the corresponding site of the AMPK
1 (R70Q) or2 (R302Q) leads to increased or decreased kinase activity,
respectively, when measured in the presence of AMP (44, 45). Our data
support a role for the 3 R225Q as an activating mutation, as judged by
its biological effects, because this substitution rendered the opposing
changes in the gene expression profile compared with the changes
resulting from genetic ablation of the AMPK 3-subunit (Fig. 1).
Thewide array of differentially expressed genes reported in this study
has not previously been identified to be regulated by AMPK.Moreover,
the biological function of a number of the regulated transcripts is poorly
described in skeletal muscle and 19 of the differentially expressed genes
remain unknown. Therefore, additional molecular and functional stud-
ies will be required to understand the full biological significance of the
transcriptional changes described here. Importantly, the expression of
several genes with known function in fat and carbohydrate metabolism
and skeletal muscle ergogenics was coordinately and reciprocally
changed in AMPK 3 R225Q transgenic and knock-out mice. Thus, the
transcriptional regulation by AMPK 3-containing complexes could
lead to at least some of the physiological differences observed in skeletal
muscle from TgPrkag3225Q and Prkag3/ mice (Fig. 3).
FIGURE 3. Contrasting transcriptional and physiological responses in the skeletal
muscle from AMPK 3 R225Q transgenic and knock-out mice. A schematic illustra-
tion of the selected transcriptional changes (A) in TgPrkag3225Q (indicated by red arrows)
and Prkag3/ mice (indicated by blue arrows), compared with wild-type littermates,
and the predicted physiological response (B). The role of AMPK3 in regulation of func-
tions like glycogen deposition, glucose uptake, oxidative metabolism, and muscle
fatigue has previously been described (17, 18). The current study provides a transcrip-
tional mechanism for the physiological differences between the genotypes.
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One of the most distinct physiological differences between skeletal
muscle from AMPK 3 R225Q transgenic and knock-out mice is the
change in glycogen metabolism (17). Glycogen content in skeletal mus-
cle from TgPrkag3225Q mice is 2-fold higher under either fed or fasted
conditions. Furthermore, skeletal muscle glycogen re-synthesis after
exercise is markedly enhanced in TgPrkag3225Q mice. In contrast, gly-
cogenesis after exercise was impaired in Prkag3/ mice (17). Glycogen
synthase catalyzes a rate-determining step in the glycogen biosynthesis
pathway. However, at least in situations where glycogen synthase is
activated, the reactions mediated by other enzymes in synthesis path-
way can become rate-limiting (46). Interestingly, the microarray data
and qRT-PCR analysis revealed a significant up- and down-regulation of
Ugp2 and Gbe1mRNAs (encoding two key enzymes in glyocogen syn-
thesis) in skeletal muscle fromAMPK 3 R225Q transgenic and knock-
out mice, respectively. In agreement with these results, the protein level
and enzyme activity of Ugp2 and Gbe1 is increased in RN pigs carrying
an R225Q mutant form of the AMPK 3-subunit (14, 47). Based on
these observations, we hypothesize that the differences in the skeletal
muscle glycogen re-synthesis rate displayed by 3 R225Q transgenic
and knock-out mice may be at least partly explained by coordinated
differential transcription of Ugp2 and Gbe1.
Activation of AMPK either by physiological stimulation such asmus-
cle contraction or by the pharmacological activator 5-amino-4-imidaz-
ole-carboxamide riboside (AICAR) leads to an increase in skeletal mus-
cle glucose transport by promoting Glut4 translocation to the cell
surface (48), as well as increasingGlut4 gene transcription (49). Impor-
tantly, the AICAR effect on glucose uptake is completely abolished in
AMPK 3 knock-out mice, suggesting that the 3-subunit is essential
for AICAR-induced glucose transport in skeletal muscle (17). Nonethe-
less, our microarray data did not detect any difference in the expression
of the Glut4 gene when comparing skeletal muscle from TgPrkag3225Q
and Prkag3/ mice. Mapk14 (also known as p38 MAPK) has been
implicated as a downstream mediator of AMPK signaling to glucose
transport in response to AICAR. In this context, it is interesting to note
that mRNAs encoding two proteins involved in regulation of the phos-
phorylation pattern ofMapk14,Map2k6 andDusp10, were coordinately
and reciprocally regulated in AMPK 3 R225Q and knock-out mice.
Another mediator implicated in AMPK-regulated glucose transport is
nitric-oxide synthase, Nos (50). The microarray and qRT-PCR analyses
revealed the mRNA encoding Nos1, the predominant nitric-oxide syn-
thase isoform in skeletal muscle, was significantly up- and down-regu-
lated by 2-fold in TgPrkag3225Q and Prkag3/ muscle, respectively.
Thus, the present study provides the first evidence of Nos1 being a
transcriptional target of AMPK signaling.
Previously, the AMPK 3-subunit has been shown to influence mus-
cle ergogenics (18). In response to electrically stimulated muscle con-
traction, isolated EDL muscle from TgPrkag3225Q mice is resistant to
fatigue. Conversely, skeletal muscle from Prkag3/ mice is fatigue
prone (18). The increase in glycogen content in skeletal muscle of
TgPrkag3225Qmicemay have a direct positive effect onmuscle perform-
ance. Additionally, skeletalmuscle is known to adapt to endurance exer-
cise by increasing the oxygen carrying capacity. Our microarray data
demonstrate a coordinated up-regulation of genes involved in the stor-
age (Ftl1) and use (Alas1) of cellular iron in TgPrkag3225Q mice, which
may indicate improved iron status and correspondingly, increased oxi-
dative capacity in skeletalmuscle. Accordingly, the level of skeletalmus-
cle oxygen carrying protein, myoglobin, was increased in TgPrkag3225Q
mice, compared with the wild-type mice.
Endurance exercise is dependent upon oxidation of fatty acids as a
major source of ATP. Two transcription factors implicated in the reg-
ulation of fatty acid homeostasis, Ppargc1a and Srebf1, as well as several
genes necessary for the transport (Cd36) and utilization (Ces3 and
Oxct1) of fatty acids were differentially expressed in skeletal muscle
fromTgPrkag3225Qmice, suggesting increased fatty acid availability and
oxidation. In agreement with these observations, elevated reliance of
fat-derived energy has been described in 3 R225Q transgenic mice
during exercise, as well as after challenge with high fat diet (17, 18).
We have applied global transcriptome analysis by oligonucleotide
microarrays to systematically characterize the role of the AMPK
3-subunit in the regulation of gene expression. Recently, a number of
studies have used qRT-PCR analysis to characterize the role of AMPK
complexes in transcription regulation (51, 52). However, gene array
approaches allow for concurrent analysis of global mRNA profiles and
offer an advantage of reducing bias in data collection, compared with
the candidate gene-based approaches. Taken together, our data indicate
that a number of genes involved in carbohydrate and fat metabolism, as
well as skeletal muscle ergogenics are coordinately and reciprocally reg-
ulated in the skeletal muscle from AMPK 3 R225Q transgenic and
knock-out mice and provide a molecular mechanism for the previously
described physiological differences between the models. Furthermore,
the current study identifies that AMPK 3-containing complexes play
an important role in regulation of novel downstream targets and path-
ways in skeletal muscle.
AMPK has been identified as an attractive therapeutic target in the
treatment of obesity and type II diabetes (53). However, the ideal ther-
apeutic small molecule should modify the activity of AMPK heterotri-
mers in metabolic tissues such as skeletal muscle to increase fatty acid
oxidation and glucose uptake without exerting any effect on organs
including central nervous system, heart, pancreas, or lung, where
AMPK activation potentially would lead to harmful consequences (54–
57). Therefore, therapeutic agents that selectively modulate the activity
of 3-containing AMPK heterotrimers could potentially provide a way
to specifically target skeletal muscle and thereby prevent any adverse
effects in other organ types. The current study contributes to the under-
standing of the role of the AMPK 3-subunit in the regulation of gene
transcription and defines several sets of potential biomarkers to charac-
terize the molecular effects in response to the administration of lead
substances ideally mimicking theTgPrkag3225Q phenotypes inmice and
pigs.
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